Prosecution Insights
Last updated: October 02, 2026
Application No. 18/294,477

5'UTR VARIANT SEQUENCE OF GENE ENCODING PHOSPHOENOLPYRUVATE CARBOXYLASE, AND USES THEREOF

Non-Final OA §112
Filed
Feb 01, 2024
Priority
Dec 24, 2021 — RE 10-2021-0187237 +1 more
Examiner
LEWIS, PATRICK T
Art Unit
1657
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
CJ CheilJedang Corporation
OA Round
1 (Non-Final)
74%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
88%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allowance Rate
863 granted / 1166 resolved
+14.0% vs TC avg
Moderate +14% lift
Without
With
+14.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
25 currently pending
Career history
1182
Total Applications
across all art units

Statute-Specific Performance

§101
6.1%
-33.9% vs TC avg
§103
31.8%
-8.2% vs TC avg
§102
19.7%
-20.3% vs TC avg
§112
22.5%
-17.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1166 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Group I (claims 1-7 and 14-15) in the reply filed on April 13, 2026 is acknowledged. Claims 8-12 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on April 13, 2026. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-3, 5-7, and 14 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 1, the text “in which one or more bases…NO: 1 are mutated” renders claims reading upon said text indefinite as text is insufficient to apprise one of ordinary skill of the metes and bounds of claimed mutant polynucleotide. One or more bases may be mutated. It is unclear what mutation(s) are required/allowed to perform the function of encoding a mutant 5’UTR. Thus, the metes and bounds of a polynucleotide applicant intends to be part of the claimed invention would have been unclear to one of ordinary skill in the art as the claimed function is not correlated to a structure(s). The deficiency is not cured in claims 2-3, 5-7, and 14. Regarding claim 7, the term “including” renders the claim indefinite as it is unclear if applicant intends for the limitations appearing after said term to be part of the claimed invention. Conclusion Claims 1-12 and 14-15 are pending. Claims 8-12 are withdrawn. Claims 1-3, 5-7, and 14 are rejected. Claims 4 and 15 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. No claims are allowed. Contacts Any inquiry concerning this communication or earlier communications from the examiner should be directed to PATRICK T LEWIS whose telephone number is (571)272-0655. The examiner can normally be reached Monday to Friday, 10 AM to 4 PM EST (Maxi Flex). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor can be reached at (571) 272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PATRICK T LEWIS/Primary Examiner, Art Unit 1691 /PL/
Read full office action

Prosecution Timeline

Feb 01, 2024
Application Filed
Jun 22, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12746251
NIRAN INTERFERING DRUGS FOR SARS-COV-2 MUTANT THERAPY
3y 5m to grant Granted Sep 29, 2026
Patent 12741983
ARTIFICIAL NUCLEIC ACID, METHOD FOR PRODUCING SAME, AND USE THEREOF
3y 6m to grant Granted Sep 22, 2026
Patent 12740994
NUTRITIONAL COMPOSITION FOR STIMULATIONG BIFIDOBACTERIA
2y 11m to grant Granted Sep 22, 2026
Patent 12734242
CARBOHYDRATE DERIVATIVES AND KITS FOR CELL SURFACE LABELING
2y 9m to grant Granted Sep 15, 2026
Patent 12729219
PROCESSES FOR PREPARING OLIGONUCLEOTIDES
3y 8m to grant Granted Sep 08, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
74%
Grant Probability
88%
With Interview (+14.5%)
2y 3m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1166 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month